NVAX
Novavax IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.31B
P/E Ratio
3.09
EPS
$2.58
Beta
2.65
52W High
$11.97
52W Low
$5.80
50-Day MA
$9.12
200-Day MA
$8.19
Dividend Yield
—
Profit Margin
39.20%
Forward P/E
2.58
PEG Ratio
1.32
About Novavax Inc
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $1.12B |
| Gross Profit (TTM) | $713.62M |
| EBITDA | $590.85M |
| Operating Margin | 14.20% |
| Return on Equity | -898.00% |
| Return on Assets | 25.70% |
| Revenue/Share (TTM) | $6.93 |
| Book Value | $-0.79 |
| Price-to-Book | 33.20 |
| Price-to-Sales (TTM) | 1.17 |
| EV/Revenue | 0.726 |
| EV/EBITDA | 1.66 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | 66.60% |
| Shares Outstanding | $164.43M |
| Float | $140.22M |
| % Insiders | 5.00% |
| % Institutions | 69.18% |
Historical Volatility
HV 10-Day
27.79%
HV 20-Day
43.95%
HV 30-Day
47.55%
HV 60-Day
64.59%
HV Rank
15.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($14.00 target)
5
Buy1
Hold1
Sell2
Strong SellData last updated: 4/30/2026